Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study-Reference-Cited by-同舟云学术

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

Published:2019-12-13 Issue: Volume: Page:
ISSN:2049-9434
Container-title:Biomedical Reports
language:
Short-container-title:biom rep

Author:

Bersanelli Melissa¹,Lattanzi Elisabetta²,D'Abbiero Nunziata²,Buti Sebastiano³,Leonetti Alessandro³,Can� Maria²,Trapani Salvatore³,Gravina Gianluca⁴,Porzio Giampiero⁴,Cannita Katia⁵,Di Marino Pietro⁶,Grassadonia Antonino⁷,Tinari Nicola⁷,De Tursi Michele⁷,Giaiacopi Elisa³,Michiara Maria³,Bordi Paola³,Perrone Fabiana³,Caravatta Luciana⁸,Trignani Marianna⁸,Genovesi Domenico⁸,Natoli Clara⁷,Ficorella Corrado⁴,Tiseo Marcello¹,Cortellini Alessio⁴

Affiliation:

1. Department of Medicine and Surgery, University Hospital of Parma, I‑43126 Parma, Italy

2. Radiotherapy Unit, University Hospital of Parma, I‑43126 Parma, Italy

3. Medical Oncology Unit, University Hospital of Parma, I‑43126 Parma, Italy

4. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, I‑67100 L'Aquila, Italy

5. Medical Oncology Unit, St. Salvatore Hospital, I‑67100 L'Aquila, Italy

6. Clinical Oncology Unit, Santissima Annunziata Hospital, Gabriele D'Annunzio University of Chieti‑Pescara, I‑66100 Chieti, Italy

7. Department of Medical, Oral and Biotechnological Sciences, Gabriele D'Annunzio University of Chieti‑Pescara, I‑66100 Chieti, Italy

8. Department of Radiation Oncology, Santissima Annunziata Hospital, Gabriele D'Annunzio University of Chieti‑Pescara, I‑66100 Chieti, Italy

Publisher

Spandidos Publications

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment;Heliyon;2024-01

2. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons;Cell Communication and Signaling;2022-04-07

3. Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies;Cancers;2021-09-29

4. Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020;Frontiers in Oncology;2021-05-12

5. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study;European Journal of Cancer;2021-05